Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through 5 years (252 weeks), and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks). These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMFYA is the first and only selective interleukin (IL)-23 inhibitor therapy approved in the U.S. to treat both adults with moderate to severe plaque PsO who are candidates for systemic therapy or phototherapy and adults with active PsA.
"People living with psoriatic disease can face a lifetime of physical pain and discomfort, which places a significant burden on their lives," said Kristian Reich,b MD, PhD, professor of translational research in inflammatory skin diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Germany, and lead author of the VOYAGE 2 study. "The signs and symptom improvements seen with TREMFYA are noteworthy for both patients who live with fear of disease recurrence and their physicians, as these data add to a growing body of evidence for this first-in-class IL-23 inhibitor treatment for moderate to severe plaque psoriasis and active psoriatic arthritis."
"The durable response rates seen in the majority of patients enrolled in the VOYAGE and DISCOVER trials further demonstrate the important role that TREMFYA has in helping patients with their moderate to severe plaque psoriasis and their active psoriatic arthritis and add to the volume of scientific insights provided by the comprehensive TREMFYA research program," said Lloyd S. Miller, MD, PhD, vice president, immunodermatology disease area leader, Janssen Research & Development, LLC.
New Phase 3 Data Showed First-in-Class TREMFYA® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA). Cision PR Newswire. April 23, 2021. Accessed April 24, 2021. https://www.prnewswire.com/news-releases/new-phase-3-data-showed-first-in-class-tremfya-guselkumab-provided-durable-complete-skin-clearance-through-five-years-in-moderate-to-severe-plaque-psoriasis-pso-and-robust-joint-symptom-improvement-through-52-weeks-in-active--301275807.html?tc=eml_cleartime